- Our Team
- For Patients
- Treatments & Services
- Medical Professionals
Breast Cancer
Clinical Trial Search
Trial Protocol ID
USOR 23189_DB-1303-O-3002_DYNASTY-Breast02
Investigator
Courtney Ackerman, M.D.
A Phase 3, Randomized, Multi-center, Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02)
Trial Protocol ID
USOR 22326_D8535C00001_CAMBRIA-2
Investigator
Carol Tweed, M.D.
A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)
Trial Protocol ID
USOR 22159_CELC-G-301_VIKTORIA-1
Investigator
Jeanine L Werner, M.D.
A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-Of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1)
Trial Protocol ID
USOR 22187_D926XC00001_TROPION
Investigator
Yousuf A. Gaffar, M.D.
A Phase 3 Open-Label, Randomised Study of Datopotamab Deruxtecan (Dato-Dxd) with or without Durvalumab versus Investigator’s Choice of Therapy in Patients with Stage I-III Triple-Negative Breast Cancer who have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)
Trial Protocol ID
USOR 20326_TOL2506A_OVELIA
Investigator
Carol Tweed, M.D.
A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Trial Protocol ID
USOR 20417_D933LC00001_BEGONIA
Investigator
Andrew Mener, M.D.
A Phase IB/II, 2-Stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) + Paclitaxel and Durvalumab (MEDI4736) in Combination With Novel Oncology Therapies With or Without Paclitaxel for First-line Metastatic Triple Negative Breast Cancer
Trial Protocol ID
USOR 21455_WO43571_heredERA
Investigator
Jeanine L Werner, M.D.
A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Giredestrant in Combination with Phesgo versus Phesgo after Induction Therapy with Phesgo+Taxane in Patients with Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally-Advanced or Metastatic Breast Cancer
Trial Protocol ID
USOR 21462_GLSI-21-01_FLAMINGO
Investigator
Jeanine L Werner, M.D.
A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Trastuzumab-based Therapy (FLAMINGO-01)
Trial Protocol ID
USOR 22080_D8531C00002_CAMBRIA
Investigator
Carol Tweed, M.D.
CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence
Trial Protocol ID
D9673R00025_DESTINY
Investigator
Carol Tweed, M.D.
DESTINY BREAST - RESPOND A multi-center, multi-country prospective observational study of patients initiating T-DXd in the first or second treatment line for HER2+, and HER2-low unresectable and/or metastatic breast cancer
Trial Protocol ID
USOR 17079_Flex Registry
Investigator
Tejaswi R. Sastry, M.D.
MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene Expression Profiles: An Adaptable Registry (FLEX Registry)